{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:24:00Z","timestamp":1789392240037,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[1999,2,1]],"date-time":"1999-02-01T00:00:00Z","timestamp":917827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[1999,2]]},"DOI":"10.4065\/74.2.137","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:16:10Z","timestamp":1232759770000},"page":"137-145","source":"Crossref","is-referenced-by-count":21,"title":["Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in Patients With Recurrent Glioma"],"prefix":"10.4065","volume":"74","author":[{"given":"Jan C.","family":"Buckner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Malkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddie","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence L.","family":"Cascino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M.","family":"Ames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.Y.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silam","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4065\/74.2.137_bib1","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1001\/jama.1992.03480210086037","article-title":"\u2018Antineoplastons\u2019: an unproved cancer therapy","volume":"267","author":"Green","year":"1992","journal-title":"JAMA"},{"key":"10.4065\/74.2.137_bib2","series-title":"Recent Advances m Chemotherapy","first-page":"2506","article-title":"Phase II clinical trials of antnieoplaston A10 and AS2-1 infusions in astrocytoma","author":"Burzynski","year":"1991"},{"key":"10.4065\/74.2.137_bib3","first-page":"10","article-title":"Antineoplastons: request for phase II trials in CNS malignancies","volume":"10","year":"1992","journal-title":"CTEPLett"},{"key":"10.4065\/74.2.137_bib4","first-page":"1988","article-title":"Phenylacetate: a novel nontoxic inducer of tumor cell differentiation","volume":"52","author":"Samid","year":"1992","journal-title":"Cancer Res"},{"key":"10.4065\/74.2.137_bib5","first-page":"891","article-title":"Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria","volume":"54","author":"Samid","year":"1994","journal-title":"Cancer Res"},{"key":"10.4065\/74.2.137_bib6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3171\/jns.1995.83.4.0672","article-title":"Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate","volume":"83","author":"Stockhammer","year":"1995","journal-title":"J Neurosurg"},{"issue":"Suppl 1","key":"10.4065\/74.2.137_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.1991.tb08127.x","article-title":"Interferon in combination with antitumourigenic phenyl derivatives: poterrtiation of IFN\u03b1 activity in-vrtro","volume":"79","author":"Samid","year":"1991","journal-title":"Br J Haematol"},{"key":"10.4065\/74.2.137_bib8","first-page":"2923","article-title":"Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate","volume":"54","author":"Ram","year":"1994","journal-title":"Cancer Res"},{"key":"10.4065\/74.2.137_bib9","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0026-895X(25)09027-3","article-title":"Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene","volume":"49","author":"Danesi","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.4065\/74.2.137_bib10","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/0006-2952(95)02013-3","article-title":"Cytostatc activity of phenylacetate and derivatives against tumor cells: correlation with lipophilicity and inhibition of protein prenylation","volume":"50","author":"Hudglns","year":"1995","journal-title":"Blochem Pharmacol"},{"key":"10.4065\/74.2.137_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1006\/cyto.1995.0061","article-title":"Transcriptional upregulation of TGF-alpha by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells","volume":"7","author":"Liu","year":"1995","journal-title":"Cytokine"},{"key":"10.4065\/74.2.137_bib12","series-title":"Histological Typing of Tumours of the Central Nervous System","author":"Kleihues","year":"1993"},{"key":"10.4065\/74.2.137_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"10.4065\/74.2.137_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1203\/00006450-199102000-00009","article-title":"Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion","volume":"29","author":"Brusilow","year":"1991","journal-title":"PediatrRes"},{"key":"10.4065\/74.2.137_bib15","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1080\/10826079408013507","article-title":"A simultaneous assay of the differentiating agents, phenylacetic acid and phenylbutyric acid, and one of their metabolites, phenylacetylglutamine, by reversed-phase, high performance liquid chromatogra-phy","volume":"17","author":"Thibault","year":"1994","journal-title":"J Liquid Chromatogr"},{"key":"10.4065\/74.2.137_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0021-9258(18)87245-3","article-title":"Toxicity of phenylacetic acid","volume":"40","author":"Sherwln","year":"1919","journal-title":"J Biol Chem"},{"key":"10.4065\/74.2.137_bib17","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/j.1471-4159.1985.tb07232.x","article-title":"A biochemical explanation of phenyl acetate neurotoxicity in experimental phenylketonuria","volume":"45","author":"Loo","year":"1985","journal-title":"J Neurochem"},{"key":"10.4065\/74.2.137_bib18","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1471-4159.1984.tb02819.x","article-title":"On the possible mechanism of phenylacetate neurotoxicity: inhibition of choline acetyltransferase by phenytacetyl-CoA","volume":"42","author":"Potempska","year":"1984","journal-title":"J Neurochem"},{"key":"10.4065\/74.2.137_bib19","first-page":"1690","article-title":"A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer","volume":"54","author":"Thibault","year":"1994","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"10.4065\/74.2.137_bib20","first-page":"l","article-title":"Antineoplastons; history of the research (1)","volume":"12","author":"Burzynski","year":"1986","journal-title":"Drugs Exp Clin Res"},{"key":"10.4065\/74.2.137_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0304-3835(94)03621-O","article-title":"Cellular accumulation of antineoplaston AS2- 1 in human hepatoma cells","volume":"88","author":"Soltysiak-Pawluezuk","year":"1995","journal-title":"Cancer Lett"},{"key":"10.4065\/74.2.137_bib22","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1002\/1097-0142(19950615)75:12<2932::AID-CNCR2820751221>3.0.CO;2-P","article-title":"Phase I study of phenylacetate administered twice daily to patients with cancer","volume":"75","author":"Thibault","year":"1995","journal-title":"Cancer"},{"key":"10.4065\/74.2.137_bib23","first-page":"156","article-title":"A phase II trial of phenylacetic acid for recurrent malignant glioma: preliminary report of the North American Brain Tumor Consortium [abstract]","volume":"15","author":"Prados","year":"1996","journal-title":"Program Proc Am Soc Clin Oncol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611638354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611638354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T05:57:00Z","timestamp":1738907820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611638354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,2]]}},"alternative-id":["S0025619611638354"],"URL":"https:\/\/doi.org\/10.4065\/74.2.137","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[1999,2]]}}}